| Package | fhir.nachc.hiv-cds |
| Type | ConceptMap |
| Id | Id |
| FHIR Version | R4 |
| Source | http://fhir.org/guides/nachc/hiv-cds/https://build.fhir.org/ig/cqframework/hiv-cds/ConceptMap-CPT.html |
| Url | http://fhir.org/guides/nachc/hiv-cds/ConceptMap/CPT |
| Version | 0.1.0 |
| Status | draft |
| Date | 2024-08-12T19:50:21+00:00 |
| Name | CPT |
| Title | CPT |
| Experimental | False |
| Realm | us |
| Authority | hl7 |
| Description | Concept mapping from content extended codes to CPT |
| Copyright | Copyright National Association of Community Health Centers, Inc. (NACHC) |
No resources found
| CodeSystem | |
http://www.ama-assn.org/go/cpt  | Current Procedural Terminology (CPT®) |
| hiv-custom | Extended Codes CodeSystem |
Note: links and images are rebased to the (stated) source
Generated Narrative: ConceptMap CPT
Mapping from (not specified) to (not specified)
DRAFT. Published on 2024-08-12 19:50:21+0000 by National Association of Community Health Centers, Inc. (NACHC) (https://www.nachc.org/). Copyright National Association of Community Health Centers, Inc. (NACHC)
Concept mapping from content extended codes to CPT
Group 1 Mapping from Extended Codes CodeSystem to Current Procedural Terminology (CPT®)
| Source Code | Relationship | Target Code |
| NACHC.B2.DE103 (Antinuclear antibodies (ANA)) | is equivalent to | 86038 (Antinuclear antibodies (ANA)) |
| NACHC.B2.DE104 (Hepatitis C antibody) | is equivalent to | 86803 (Hepatitis C antibody) |
| NACHC.B2.DE105 (Hepatitis C antibody; confirmatory test (eg, immunoblot)) | is equivalent to | 86804 (Hepatitis C antibody; confirmatory test (eg, immunoblot)) |
| NACHC.B2.DE106 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique) | is equivalent to | 87520 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique) |
| NACHC.B2.DE107 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed) | is equivalent to | 87521 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed) |
| NACHC.B2.DE108 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed) | is equivalent to | 87522 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed) |
| NACHC.B2.DE109 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus) | is equivalent to | 87902 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus) |
| NACHC.B2.DE113 (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)) | is equivalent to | 3218F (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)) |
| NACHC.B2.DE114 (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)) | is equivalent to | 3220F (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)) |
| NACHC.B2.DE115 (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)) | is equivalent to | 3265F (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)) |
| NACHC.B2.DE116 (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)) | is equivalent to | 3266F (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)) |
| NACHC.B2.DE117 (Hepatitis C screening documented as performed (HIV)) | is equivalent to | 3514F (Hepatitis C screening documented as performed (HIV)) |
| NACHC.B2.DE118 (Patient receiving antiviral treatment for Hepatitis C (HEP-C)) | is equivalent to | 4150F (Patient receiving antiviral treatment for Hepatitis C (HEP-C)) |
| NACHC.B2.DE119 (Collection of venous blood by venipuncture) | is equivalent to | 36415 (Collection of venous blood by venipuncture) |
| NACHC.B2.DE120 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver) | is equivalent to | 81596 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver) |
FHIR{
"resourceType" : "ConceptMap",
"id" : "CPT",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ConceptMap CPT</b></p><a name=\"CPT\"> </a><a name=\"hcCPT\"> </a><a name=\"CPT-en-US\"> </a><p>Mapping from (not specified) to (not specified)</p><p>DRAFT. Published on 2024-08-12 19:50:21+0000 by National Association of Community Health Centers, Inc. (NACHC) (<a href=\"https://www.nachc.org/\">https://www.nachc.org/</a>). Copyright National Association of Community Health Centers, Inc. (NACHC)</p><div><p>Concept mapping from content extended codes to CPT</p>\n</div><br/><p><b>Group 1 </b>Mapping from <a href=\"CodeSystem-hiv-custom.html\">Extended Codes CodeSystem</a> to <a href=\"http://terminology.hl7.org/6.0.2/CodeSystem-CPT.html\">Current Procedural Terminology (CPT®)</a></p><table class=\"grid\"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td></tr><tr><td>NACHC.B2.DE103 (Antinuclear antibodies (ANA))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>86038 (Antinuclear antibodies (ANA))</td></tr><tr><td>NACHC.B2.DE104 (Hepatitis C antibody)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>86803 (Hepatitis C antibody)</td></tr><tr><td>NACHC.B2.DE105 (Hepatitis C antibody; confirmatory test (eg, immunoblot))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>86804 (Hepatitis C antibody; confirmatory test (eg, immunoblot))</td></tr><tr><td>NACHC.B2.DE106 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>87520 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique)</td></tr><tr><td>NACHC.B2.DE107 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>87521 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed)</td></tr><tr><td>NACHC.B2.DE108 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>87522 (Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed)</td></tr><tr><td>NACHC.B2.DE109 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>87902 (Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus)</td></tr><tr><td>NACHC.B2.DE113 (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>3218F (RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C))</td></tr><tr><td>NACHC.B2.DE114 (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>3220F (Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C))</td></tr><tr><td>NACHC.B2.DE115 (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>3265F (Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C))</td></tr><tr><td>NACHC.B2.DE116 (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>3266F (Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C))</td></tr><tr><td>NACHC.B2.DE117 (Hepatitis C screening documented as performed (HIV))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>3514F (Hepatitis C screening documented as performed (HIV))</td></tr><tr><td>NACHC.B2.DE118 (Patient receiving antiviral treatment for Hepatitis C (HEP-C))</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>4150F (Patient receiving antiviral treatment for Hepatitis C (HEP-C))</td></tr><tr><td>NACHC.B2.DE119 (Collection of venous blood by venipuncture)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>36415 (Collection of venous blood by venipuncture)</td></tr><tr><td>NACHC.B2.DE120 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver)</td><td><a href=\"http://hl7.org/fhir/extensions/5.1.0/CodeSystem-concept-map-equivalence.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>81596 (Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver)</td></tr></table></div>"
},
"url" : "http://fhir.org/guides/nachc/hiv-cds/ConceptMap/CPT",
"version" : "0.1.0",
"name" : "CPT",
"title" : "CPT",
"status" : "draft",
"experimental" : false,
"date" : "2024-08-12T19:50:21+00:00",
"publisher" : "National Association of Community Health Centers, Inc. (NACHC)",
"contact" : [
{
"telecom" : [
{
"system" : "url",
"value" : "https://www.nachc.org/"
}
]
}
],
"description" : "Concept mapping from content extended codes to CPT",
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "840"
}
]
}
],
"copyright" : "Copyright National Association of Community Health Centers, Inc. (NACHC)",
"group" : [
{
"source" : "http://fhir.org/guides/nachc/hiv-cds/CodeSystem/hiv-custom",
"target" : "http://www.ama-assn.org/go/cpt",
"element" : [
{
"code" : "NACHC.B2.DE103",
"display" : "Antinuclear antibodies (ANA)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "86038",
"display" : "Antinuclear antibodies (ANA)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE104",
"display" : "Hepatitis C antibody",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "86803",
"display" : "Hepatitis C antibody",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE105",
"display" : "Hepatitis C antibody; confirmatory test (eg, immunoblot)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "86804",
"display" : "Hepatitis C antibody; confirmatory test (eg, immunoblot)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE106",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "87520",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE107",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "87521",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE108",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "87522",
"display" : "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE109",
"display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "87902",
"display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE113",
"display" : "RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "3218F",
"display" : "RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE114",
"display" : "Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "3220F",
"display" : "Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE115",
"display" : "Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "3265F",
"display" : "Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE116",
"display" : "Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "3266F",
"display" : "Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE117",
"display" : "Hepatitis C screening documented as performed (HIV)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "3514F",
"display" : "Hepatitis C screening documented as performed (HIV)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE118",
"display" : "Patient receiving antiviral treatment for Hepatitis C (HEP-C)",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "4150F",
"display" : "Patient receiving antiviral treatment for Hepatitis C (HEP-C)",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE119",
"display" : "Collection of venous blood by venipuncture",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "36415",
"display" : "Collection of venous blood by venipuncture",
"equivalence" : "equivalent"
}
]
},
{
"code" : "NACHC.B2.DE120",
"display" : "Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",
"target" : [
{
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/1.0/StructureDefinition/extension-ConceptMap.element.target.equivalence",
"valueCode" : "equivalent"
}
],
"code" : "81596",
"display" : "Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",
"equivalence" : "equivalent"
}
]
}
]
}
]
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.